Added to YB: 2024-01-24
Pitch date: 2024-01-23
GMAB [bullish]
Genmab A/S
+4.84%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Market Cap
DKK 19.5B
Pitch Price
DKK 1.9K
Price Target
N/A
Dividend
N/A
EV/EBITDA
10.89
P/E
12.61
EV/Sales
4.22
Sector
Biotechnology
Category
value
Show full summary:
Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade)
GMAB undervalued 30% below Aug price despite JNJ arbitration loss; Darzalex strong but missed 2023 target; Epkinly w/ ABBV shows promise; solid financials w/ $4B cash; pipeline & GEN3014 vs Darzalex Faspro key catalysts; price doesn't reflect full potential
Read full article (6 min)